The efficacy and safety of apatinib in Ewing’s sarcoma: a retrospective analysis in one institution

Abstract

Apatinib may provide as second- or first-line treatment options for ES patients, particularly in chemoresistant cases. Further studies with more cases and longer follow-up will be necessary to determine the clinical efficacy and safety of apatinib in ES patients.